Effects of streptozotocin-induced diabetes in apolipoprotein AI deficient mice
Authors Ira J. Goldberg, Aaron Isaacs, Ephraim Sehayek, Jan L. Breslow, Li-Shin Huang
Submitted By Ira Goldberg on 3/5/2004
Status Published
Journal Atherosclerosis
Year 2004
Date Published 1/1/2004
Volume : Pages 172 : 47 - 53
PubMed Reference 14709356
Abstract During the past decade a number of investigators have attempted to develop mouse
models of diabetic macrovascular disease. Hyperglycemia might increase vascular
damage because it increases oxidant stress. For this reason we studied animals
that were deficient in HDL; HDL is widely believed to protect against oxidant
stress. An inbred line of mice doubly deficient in LDL receptor and apoAI was
made diabetic with streptozotocin (STZ); control mice had an average glucose of
7.2 ± 2 mmol/L and STZ-treated mice had an average glucose of 19.4 ± 6.5 mmol/L.
The animals were fed a high cholesterol but low fat diet leading to plasma
cholesterol levels of 9.4 ± 1.6 mmol/L in control animals and 10.1 ± 1.8 mmol/L
in STZ-treated mice. The control and STZ-treated animals had similar plasma
lipoprotein profiles. Atherosclerosis assessed at 23 weeks averaged 38154 µm2 in
control and 32962 µm2 in STZ-treated mice. Therefore STZ-induced diabetes does
not alter plasma lipoproteins or atherosclerosis in HDL deficient mice.


Apoa1apolipoprotein A-I
Ldlrlow density lipoprotein receptor